tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Personal Finance CenterMortgagesLoansInvesting & RetirementSpending & Savings
Calculators
401k Retirement CalculatorMortgage Calculator
Popular
Compound Interest CalculatorDollar Cost Averaging
New
Student Loan CalculatorAuto Loan Calculator
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

KA Stock Latest News

Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate Activities
Press ReleasesKineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate Activities
2M ago
KA
Kineta Rolls Out New Stock and Cash Incentive Plans
PremiumCompany Announcements
Kineta Rolls Out New Stock and Cash Incentive Plans
3M ago
8K
KA
Kineta Reports Progress in KVA12123 Cancer Trial
PremiumCompany Announcements
Kineta Reports Progress in KVA12123 Cancer Trial
3M ago
8K
KA
Kineta presents data from Phase 1/2 VISTA-101 clinical trial at AACR
PremiumThe Fly
Kineta presents data from Phase 1/2 VISTA-101 clinical trial at AACR
3M ago
KA
Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial
PremiumPress Releases
Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial
3M ago
KA
Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update
PremiumPress ReleasesKineta Reports Full Year 2023 Financial Results and Provides Corporate Update
4M ago
KA
Kineta clears additional cohorts in Phase 1/2 VISTA-101 trial
PremiumThe Fly
Kineta clears additional cohorts in Phase 1/2 VISTA-101 trial
4M ago
KA
MRK
Kineta Explores Strategic Alternatives Amid Financial Struggles
PremiumCompany Announcements
Kineta Explores Strategic Alternatives Amid Financial Struggles
4M ago
8K
KA
Kineta to reduce workforce by 64% in corporate restructuring
PremiumThe Fly
Kineta to reduce workforce by 64% in corporate restructuring
4M ago
KA
Kineta Weighs Strategic Alternatives Amid Operational Challenges
PremiumCompany Announcements
Kineta Weighs Strategic Alternatives Amid Operational Challenges
4M ago
8K
KA
Kineta to Present New Preclinical Data on its Anti-VISTA Antibody KVA12123 in Acute Myeloid Leukemia at the AACR Blood Cancer Discovery Symposium
PremiumPress Releases
Kineta to Present New Preclinical Data on its Anti-VISTA Antibody KVA12123 in Acute Myeloid Leukemia at the AACR Blood Cancer Discovery Symposium
4M ago
KA
Kineta to Present New Preclinical Data on its Anti-VISTA Antibody KVA12123 in Acute Myeloid Leukemia at the AACR Blood Cancer Discovery Symposium
PremiumPress Releases
Kineta to Present New Preclinical Data on its Anti-VISTA Antibody KVA12123 in Acute Myeloid Leukemia at the AACR Blood Cancer Discovery Symposium
4M ago
KA
Kineta to present new preclinical data on KVA12123
PremiumThe FlyKineta to present new preclinical data on KVA12123
4M ago
KA
Kineta to Present at Upcoming Investor Conferences
PremiumPress Releases
Kineta to Present at Upcoming Investor Conferences
5M ago
KA
Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors
PremiumPress Releases
Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors
6M ago
KA
Kineta provides update on ongoing Phase 1/2 VISTA-101 trial of KVA12123
PremiumThe Fly
Kineta provides update on ongoing Phase 1/2 VISTA-101 trial of KVA12123
6M ago
KA
Kineta to Participate in the 13th Annual LifeSci Partners Corporate Access Event
PremiumPress Releases
Kineta to Participate in the 13th Annual LifeSci Partners Corporate Access Event
6M ago
KA
Kineta Publishes Preclinical Data Demonstrating the Potential of Anti-VISTA Antibody KVA12123 as an Immunomodulatory Therapy for Cancer
PremiumPress Releases
Kineta Publishes Preclinical Data Demonstrating the Potential of Anti-VISTA Antibody KVA12123 as an Immunomodulatory Therapy for Cancer
7M ago
KA
Kineta publishes preclinical data on KVA12123
PremiumThe Fly
Kineta publishes preclinical data on KVA12123
7M ago
KA
Kineta to Host KOL Event to Review New Data from VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors on December 5, 2023
PremiumPress ReleasesKineta to Host KOL Event to Review New Data from VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors on December 5, 2023
7M ago
KA
Kineta to Present at the 5th Annual Macrophage-Directed Therapies Summit
PremiumPress Releases
Kineta to Present at the 5th Annual Macrophage-Directed Therapies Summit
8M ago
KA
Kineta announces new data from VISTA-101 trial of KVA12123
PremiumThe Fly
Kineta announces new data from VISTA-101 trial of KVA12123
8M ago
KA

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >